MX2024011063A - Sistemas de deposito que comprenden cariprazina o sales de esta. - Google Patents

Sistemas de deposito que comprenden cariprazina o sales de esta.

Info

Publication number
MX2024011063A
MX2024011063A MX2024011063A MX2024011063A MX2024011063A MX 2024011063 A MX2024011063 A MX 2024011063A MX 2024011063 A MX2024011063 A MX 2024011063A MX 2024011063 A MX2024011063 A MX 2024011063A MX 2024011063 A MX2024011063 A MX 2024011063A
Authority
MX
Mexico
Prior art keywords
cariprazine
depot
salts
compositions
present
Prior art date
Application number
MX2024011063A
Other languages
English (en)
Spanish (es)
Inventor
Ehud Marom
Shai Rubnov
Anna Gopin
Original Assignee
Mapi Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapi Pharma Ltd filed Critical Mapi Pharma Ltd
Publication of MX2024011063A publication Critical patent/MX2024011063A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2024011063A 2022-03-17 2023-02-14 Sistemas de deposito que comprenden cariprazina o sales de esta. MX2024011063A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263320706P 2022-03-17 2022-03-17
PCT/IL2023/050150 WO2023175598A1 (en) 2022-03-17 2023-02-14 Depot systems comprising cariprazine or salts thereof

Publications (1)

Publication Number Publication Date
MX2024011063A true MX2024011063A (es) 2024-09-23

Family

ID=88022782

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011063A MX2024011063A (es) 2022-03-17 2023-02-14 Sistemas de deposito que comprenden cariprazina o sales de esta.

Country Status (9)

Country Link
US (2) US11931357B2 (https=)
EP (1) EP4493274A4 (https=)
JP (1) JP2025509390A (https=)
CN (1) CN119136804A (https=)
AU (1) AU2023234747A1 (https=)
CA (1) CA3244202A1 (https=)
IL (1) IL315074A (https=)
MX (1) MX2024011063A (https=)
WO (1) WO2023175598A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
US12514908B2 (en) 2021-07-05 2026-01-06 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
AU2023234747A1 (en) * 2022-03-17 2024-09-12 Mapi Pharma Ltd. Depot systems comprising cariprazine or salts thereof
US20230372331A1 (en) * 2022-05-18 2023-11-23 Anxo Pharmaceutical Co., Ltd. Pharmaceutical composition
CN119424341A (zh) * 2023-08-02 2025-02-14 珠海市华海康医药科技有限责任公司 一种注射用药物缓释微球及其制备方法
CN117137864A (zh) * 2023-11-01 2023-12-01 山东则正医药技术有限公司 一种卡利拉嗪原位凝胶制剂及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
US20090036468A1 (en) * 2007-08-03 2009-02-05 Forest Laboratories Holdings Limited Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
WO2018015915A1 (en) * 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
CN108261394B (zh) 2017-01-04 2022-03-04 广东东阳光药业有限公司 一种盐酸卡利拉嗪注射制剂及其制备方法和用途
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
US11344503B2 (en) * 2019-12-13 2022-05-31 Halo Science LLC Cariprazine release formulations
WO2022003662A1 (en) 2020-06-29 2022-01-06 Mapi Pharma Ltd. Low burst-release liraglutide depot systems
AU2023234747A1 (en) * 2022-03-17 2024-09-12 Mapi Pharma Ltd. Depot systems comprising cariprazine or salts thereof

Also Published As

Publication number Publication date
US11931357B2 (en) 2024-03-19
CN119136804A (zh) 2024-12-13
CA3244202A1 (en) 2023-09-21
EP4493274A1 (en) 2025-01-22
IL315074A (en) 2024-10-01
WO2023175598A1 (en) 2023-09-21
AU2023234747A1 (en) 2024-09-12
US20240238280A1 (en) 2024-07-18
JP2025509390A (ja) 2025-04-11
US20230293515A1 (en) 2023-09-21
EP4493274A4 (en) 2026-03-18
US12251380B2 (en) 2025-03-18

Similar Documents

Publication Publication Date Title
MX2024011063A (es) Sistemas de deposito que comprenden cariprazina o sales de esta.
ES2521672T3 (es) Formulaciones farmacéuticas para el tratamiento del cáncer
MX2023005984A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
MX2023005983A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
CR20210563A (es) Compuestos y métodos para el tratamiento de covid-19
GB0226724D0 (en) Therapeutic agents
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
WO2002015903A3 (de) Neue pharmazeutische zusammensetzung zur verabreichung von n-0923
DK0828500T3 (da) Anvendelse af flavanyllignaner til fremstilling af lægemidler med proliferativ aktivitet i uturus, ovarie og bryst
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
KR950031074A (ko) 비-펩티드 타키키닌 수용체 길항물질
CY1106763T1 (el) Προληπτικα ή θεραπευτικα μεσα για φλεγμονωδεις νοσους του εντερου
GEAP202516634A (en) Heteroaryl compounds for the treatment of pain
UA81625C2 (ru) Применение ротиготина для трансепикутального лечения синдрома уставших ног
MX2023009520A (es) Compuesto de 4-aminoquinazolina.
ZA202308600B (en) Methods and pharmaceutical composition for treating diseases
MX418886B (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo
ZA202203789B (en) Long-acting injectable formulations of ketamine pamoate salts
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
TN2022000092A1 (en) Oral complement factor d inhibitors
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
EA202191130A1 (ru) Фармацевтическая композиция для лечения апластической анемии